Elevated serum advanced glycation end products and their circulating receptors are associated with anaemia in older community-dwelling women.
OBJECTIVE
to determine whether serum carboxymethyl-lysine, a dominant advanced glycation end product (AGE), and circulating total receptor for AGEs (sRAGE) and endogenous secretory receptor for AGEs (esRAGE) are associated with anaemia.


METHODS
cross-sectional analysis.


METHODS
moderately severely disabled women, > or =65 years, living in the community in Baltimore, MD (the Women's Health and Aging Study I).


METHODS
519 women with and without anaemia.


METHODS
haemoglobin and anaemia (haemoglobin <12 g/dL).


RESULTS
of 519 women, 128 (24.7%) had anaemia. All odds ratios (OR) were expressed per one standard deviation. Serum CML was associated with anaemia [OR 1.47, 95% confidence interval (CI) 1.11-1.95, P = 0.008] in a multivariate logistic regression model adjusting for age, race, smoking, education and chronic diseases. Serum sRAGE (ng/mL) and esRAGE (ng/mL) were associated with anaemia (OR 1.52, 95% CI 1.21-1.92, P = 0.0004; OR 1.49, 95% CI 1.18-1.87, P = 0.0006, respectively) in separate multivariate logistic regression models, adjusting for the same covariates mentioned above. Serum CML (P = 0.004), sRAGE (P < 0.0001) and esRAGE (P < 0.0001) were inversely and independently associated with haemoglobin concentrations.


CONCLUSIONS
AGEs and circulating RAGE are independently associated with haemoglobin and anaemia in older women. AGEs are amenable to interventions, as serum AGEs can be lowered by a change in dietary pattern and pharmacological treatment.
Semba
Richard D
RD
Johns Hopkins University School of Medicine, Baltimore, MD, USA. rdsemba@jhmi.edu
Ferrucci
Luigi
L
Sun
Kai
K
Patel
Kushang V
KV
Guralnik
Jack M
JM
Fried
Linda P
LP
D000203:Activities of Daily Living; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000097:blood* / Q000209:etiology; D015142:Baltimore; D015415:Biomarkers / Q000097:blood; D003430:Cross-Sectional Studies; D004185:Disability Evaluation; D005260:Female; D017127:Glycation End Products, Advanced / Q000097:blood*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D016015:Logistic Models; D008239:Lysine / Q000031:analogs & derivatives* / Q000097:blood; D016017:Odds Ratio; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000097:blood*; D018570:Risk Assessment; D012307:Risk Factors; D015854:Up-Regulation
D015415:Biomarkers; D017127:Glycation End Products, Advanced; D006454:Hemoglobins; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic; C048496:N(6)-carboxymethyllysine; D008239:Lysine